Literature DB >> 11196073

Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin.

L Puccetti1, F Bruni, G Bova, M Cercignani, G Pompella, A Auteri, A L Pasqui.   

Abstract

Thrombosis is a complication of atherosclerosis and monocytes play a determinant role either in the progression of atherosclerotic plaque or in blood coagulation by way of tissue factor expression. Platelets play a direct role in thrombosis and a hyperfunctional state has been described in hypercholesterolemic subjects. Moreover, platelets seem to be able to enhance monocyte activity. Cholesterol-lowering molecules (statins) are reported to reduce cardiovascular risk, either by decreasing the circulating level of cholesterol or by non-lipidic actions such as the reduction of monocyte and platelet activity. The aim of our study was to investigate the influence of platelets on the expression of tissue factor by monocytes and the effect induced by cerivastatin. We measured tissue factor levels by ELISA and the procoagulant activity of stimulated monocytes by a clotting assay on cellular preparations and whole blood in 40 hypercholesterolemic subjects (22 male, 18 female, mean age 52.7 +/- 12 years, total cholesterol 251.6 +/- 19.9 mg/dl) before and after cerivastatin addition. Tissue factor expression was enhanced in hypercholesterolemic subjects compared with normal subjects (31.6 +/- 7.6 vs. 23 +/- 5.8 pg/cells, P < 0.01). The presence of platelets increased the amount of tissue factor (55.3 +/- 7.3 pg/cells, P < 0.001) and cerivastatin reduced the expression of tissue factor in isolated monocytes, in the mixed cellular system, and in whole blood (19.6 +/- 4.1 pg/cells, P < 0.001). In conclusion, tissue factor expression by monocytes is enhanced in hypercholesterolemic subjects compared with normal controls. Platelets enhance monocyte production of tissue factor, and cerivastatin is able to counteract this prothrombotic mechanism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11196073     DOI: 10.1007/s005990070014

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  6 in total

Review 1.  Hyperlipidemia, tissue factor, coagulation, and simvastatin.

Authors:  Albert Phillip Owens; James Robert Byrnes; Nigel Mackman
Journal:  Trends Cardiovasc Med       Date:  2013-09-07       Impact factor: 6.677

2.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Authors:  A Phillip Owens; Freda H Passam; Silvio Antoniak; Stephanie M Marshall; Allison L McDaniel; Lawrence Rudel; Julie C Williams; Brian K Hubbard; Julie-Ann Dutton; Jianguo Wang; Peter S Tobias; Linda K Curtiss; Alan Daugherty; Daniel Kirchhofer; James P Luyendyk; Patrick M Moriarty; Shanmugam Nagarajan; Barbara C Furie; Bruce Furie; Douglas G Johns; Ryan E Temel; Nigel Mackman
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 3.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Simvastatin-induced Changes in the Leukocytic System of Porcine Bone Marrow.

Authors:  Anna Snarska; Dominika Wysocka; Liliana Rytel; Sławomir Gonkowski; Hanna Pawelec; Przemysław Sobiech
Journal:  J Vet Res       Date:  2018-12-10       Impact factor: 1.744

5.  Effect of Simvastatin on Thrombopoiesis in Porcine Bone Marrow.

Authors:  Anna Snarska; Dominika Wysocka; Liliana Rytel
Journal:  J Vet Res       Date:  2019-03-22       Impact factor: 1.744

6.  Association Between Air Temperature and the Incidence of Acute Coronary Heart Disease in Northeast China.

Authors:  Xue Wang; Yizeng Jiang; Yingzhe Bai; Chao Pan; Renzi Wang; Miao He; Jinghai Zhu
Journal:  Clin Interv Aging       Date:  2020-01-15       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.